Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 4:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Gastrointestinal Carcinoma Clear all
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Carcinomatosis, Fallopian Tube Cancer
Interventions
GL-ONC1 alone, or in combination with chemotherapy with or without bevacizumab
Biological
Lead sponsor
Genelux Corporation
Industry
Eligibility
21 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Newport Beach, California • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced May 22, 2026, 4:49 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Peritoneal Neoplasms, Neoplasm Metastasis, Adenocarcinoma, Sarcoma
Interventions
Not listed
Lead sponsor
Edward-Elmhurst Health System
Other
Eligibility
Not listed
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
Elmhurst, Illinois • Naperville, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced May 22, 2026, 4:49 AM EDT
Terminated Phase 1 Interventional Results available
View directory record Official record
Conditions
Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Gastric Cancer, Esophageal Cancer, Pancreas Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma, Triple-negative Breast Cancer, Ovarian Cancer, Colo-rectal Cancer, Fallopian Tube Cancer
Interventions
ADCT-301, Pembrolizumab
Drug · Biological
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Palo Alto, California • New Haven, Connecticut • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced May 22, 2026, 4:49 AM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Carcinoma Non-resectable
Interventions
mFOLFIRINOX, Algenpantucel-L Immunotherapy, SBRT, Gemcitabine
Drug · Biological · Radiation
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Louisville, Kentucky • Burlington, Massachusetts • Albuquerque, New Mexico + 1 more
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced May 22, 2026, 4:49 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatobiliary Cancer
Interventions
Target Navigation Pilot Program
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced May 22, 2026, 4:49 AM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Heptocellular Cancer, Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma, Biliary Cancer
Interventions
Tremelimumab, RFA, TACE, Cryoablation
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced May 22, 2026, 4:49 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Relapsed Pediatric Solid Tumors, Refractory Pediatric Solid Tumors, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma, Neuroblastoma, Wilms Tumor, Hepatic Tumor, Germ Cell Tumor, Desmoid Tumor
Interventions
Magnetic Resonance High Intensity Focused Ultrasound
Device
Lead sponsor
AeRang Kim
Other
Eligibility
Up to 30 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced May 22, 2026, 4:49 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, MSI-H Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Other Solid Tumors
Interventions
CDX-527
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced May 22, 2026, 4:49 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC ), Head and Neck (HNSCC), Bladder Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Advanced or Metastatic
Interventions
CP-383
Drug
Lead sponsor
Tasca Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
13
States / cities
Denver, Colorado • Orlando, Florida • Grand Rapids, Michigan + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced May 22, 2026, 4:49 AM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer
Interventions
erlotinib hydrochloride, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced May 22, 2026, 4:49 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Advanced Solid Tumor, Hepatocellular Carcinoma
Interventions
TORL-4-500
Drug
Lead sponsor
TORL Biotherapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
8
States / cities
Phoenix, Arizona • Fullerton, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced May 22, 2026, 4:49 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Pembrolizumab, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
959 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
24
States / cities
Gilbert, Arizona • Tucson, Arizona • Duarte, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced May 22, 2026, 4:49 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer
Interventions
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Wild-type Reovirus
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced May 22, 2026, 4:49 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Solid Tumor, Small Cell and Non-small Cell Lung Cancer, Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity, Squamous Cell Carcinoma of Larynx, Squamous Cell Carcinoma of Nasopharynx, Squamous Cell Carcinoma of Other Specified Sites of Skin, Malignant Melanoma, Esophageal Squamous Cell Carcinoma
Interventions
RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy, Pembrolizumab (PD-1 Blocking Antibody)
Biological · Drug
Lead sponsor
Rapa Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced May 22, 2026, 4:49 AM EDT
Completed No phase listed Observational Results available
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Technetium-99m macroaggregated albumin (Tc-99m MAA)
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
21 Years and older
Enrollment
6 participants
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced May 22, 2026, 4:49 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)
Interventions
Spevatamig (PT886), Paclitaxel, Gemcitabine, Abraxane, KEYTRUDA® (pembrolizumab), Oxaliplatin, Leucovorin, Fluorouracil, Capecitabine, FOLFIRINOX
Drug
Lead sponsor
Phanes Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
11
States / cities
Duarte, California • Los Angeles, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced May 22, 2026, 4:49 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Appendix Carcinoma, Carcinomatosis, Colorectal Carcinoma, Gastric Carcinoma, Malignant Peritoneal Neoplasm, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Pain Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced May 22, 2026, 4:49 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Cirrhosis, Liver, Hepatic Cirrhosis, Hepatocellular Carcinoma, Liver Cancer
Interventions
Not listed
Lead sponsor
Epigenomics, Inc
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Los Angeles, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced May 22, 2026, 4:49 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Cervical Cancer, Esophageal Cancer, Head and Neck Cancer, Lung Cancer, Non-melanomatous Skin Cancer, Penile Cancer
Interventions
recombinant interferon alfa, isotretinoin
Biological · Drug
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 1999
U.S. locations
6
States / cities
Newport Beach, California • Bloomington, Indiana • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated May 11, 2011 · Synced May 22, 2026, 4:49 AM EDT
Not listed Phase 2 Interventional
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreatic Neoplasms
Interventions
PEGPH20, Pembrolizumab
Drug · Biological
Lead sponsor
Pancreatic Cancer Research Team
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Gilbert, Arizona • Los Angeles, California • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced May 22, 2026, 4:49 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Cholangiocarcinoma, Stage III Gallbladder Cancer AJCC v7, Stage IIIA Gallbladder Cancer AJCC v7, Stage IIIB Gallbladder Cancer AJCC v7, Stage IV Gallbladder Cancer AJCC v7, Stage IVA Gallbladder Cancer AJCC v7, Stage IVB Gallbladder Cancer AJCC v7
Interventions
Laboratory Biomarker Analysis, Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102
Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced May 22, 2026, 4:49 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Hepatitis C, Hepatocellular Carcinoma, Ascites, Variceal Hemorrhage, Death
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced May 22, 2026, 4:49 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Adult Liver Carcinoma, Liver Cirrhosis
Interventions
18F-Fluoromisonidazole, Arterial Embolization, Computed Tomography, Positron Emission Tomography
Drug · Procedure · Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
19 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced May 22, 2026, 4:49 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Locally Advanced or Metastatic Solid Carcinomas, Colon Cancer, Cholangiocarcinoma
Interventions
TRK-950
Biological
Lead sponsor
Toray Industries, Inc
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Phoenix, Arizona • Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced May 22, 2026, 4:49 AM EDT